CapsoVision (CV) Cash from Financing Activities (2024 - 2025)

CapsoVision's (CV) quarterly Cash from Financing Activities came in at $15000.0 in Q4 2025, down 99.7% year-on-year from $5.0 million in Q4 2024, and down 99.93% quarter-over-quarter from $22.4 million in Q3 2025.

CapsoVision (CV) Cash from Financing Activities (2024 - 2025) Analysis & Trends

CapsoVision has disclosed Cash from Financing Activities across 2 years of filings, most recently posting $15000.0 for Q4 2025.

  • Cash from Financing Activities for Q4 2025 came in at $15000.0, down 99.7% year-over-year; the trailing twelve-month figure through Dec 2025 was $37.4 million (changed N/A YoY), and the FY2025 annual result was $23.6 million, up 56.59% from the prior year.
  • Cash from Financing Activities came in at $15000.0 for Q4 2025 at CapsoVision, down from $22.4 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $22.4 million in Q3 2025 to a low of $15000.0 in Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing Activities (Qtr)
1 Abbott Laboratories 152.92 Bn 146.27 Bn 6.27 Bn 17.31 Bn
2 Stryker 119.50 Bn 116.62 Bn 3.81 Bn -1.51 Bn
3 Medtronic 102.71 Bn 94.54 Bn 5.76 Bn -2.09 Bn
4 Boston Scientific 69.72 Bn 68.51 Bn 3.61 Bn -260.00 Mn
5 Edwards Lifesciences 49.24 Bn 45.57 Bn 1.29 Bn -451.20 Mn
6 GE HealthCare Technologies 29.74 Bn 27.67 Bn 1.98 Bn 21.00 Mn
7 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn -26.93 Mn
8 Dexcom 28.96 Bn 27.84 Bn 750.30 Mn -25.00 Mn
9 Steris 20.31 Bn 19.88 Bn 697.10 Mn -97.90 Mn
10 CapsoVision 176.55 Mn 166.44 Mn 1.95 Mn 15,000.00

Historic Data

Download Data
DateValue
Dec 31, 2025 15,000.00
Dec 31, 2025 15,000.00
Sep 30, 2025 22.39 Mn
Sep 30, 2025 22.39 Mn
Dec 31, 2024 5.00 Mn
Dec 31, 2024 5.00 Mn
Sep 30, 2024 10.00 Mn
Sep 30, 2024 10.00 Mn